34 results about "Cell Proliferation Process" patented technology

The present invention relates to chemical compounds having a general formula I

wherein A¹, A², C¹, C², D, L¹, L², Z and R¹- are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

The invention discloses an anti-hepatoma stem cell monoclonal antibody which is secreted by a mouse hybridoma cell 4P-120 with the collection number of CGMCC No.8800. Proven by experiments, the monoclonal antibody can be specifically combined with hepatoma cells and is capable of specifically recognizing hepatoma tissues, antigens recognized by the monoclonal antibody are highly expressed in cancer tissues of human hepatoma, but are not expressed or slightly expressed in para-carcinoma tissues, and positive-to-negative differentiation and negative-to-positive defifferentiation exist in a cell multiplication process. Compared with cells with low antigen expression, cells with high antigen expression have higher proliferation capability, clone formation capability, balling capability, scratch transfer capability and invasion transfer capability; and the invention provides a functional monoclonal antibody with an application prospect for treating hepatoma with targeted tumor stem cells, and the monoclonal antibody can be used for preparing medicines for treating hepatoma.

The present invention relates to chemical compounds having a general formula I

wherein A^1-8, D′, L¹, L², R¹, R^6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

The invention discloses a c9orf116 gene capable of regulating liver regeneration, and a siRNA (Ribonucleic Acid) interference target spot and application thereof, and belongs to the technical field of molecular biology and biological medicine. The technical scheme key point of the gene is the application of the antagonist of the c9orfll6 gene capable of regulating liver regeneration in preparing a medicine for accelerating liver regeneration. The nucleotide sequence of the c9orfll6 gene is disclosed in SEQ ID NO.1, the antagonist of the c9orf116 gene capable of regulating liver regeneration is the siRNA interference target spot expressed by a specificity interference c9orf116 gene, and the nucleotide sequence of the siRNA interference target spot is disclosed in SEQ ID No.2, SEQ ID NO.3 and SEQ ID NO.4. The c9orfll6 gene disclosed by the invention has a function for accelerating liver proliferation, the gene has an important function in a cell proliferation process, and the gene also has a potential application value on the aspects including cell proliferation and differentiation, tumor treatment, anti-tumor medicine research and development and the like.

The invention discloses a method for clustering lasso cluster characteristics based on network analysis, which is mainly used for solving the clustering of related expressed genes in bioengineering and establishing a lasso cluster model by using the method. The method comprises the steps of firstly, dividing experimental data into a positive data set and a negative data set, and respectively establishing a weighting co-expression gene network (adjacent matrix) corresponding to the positive data set or the negative data set; secondly, determining important network modules respectively corresponding to a positive sample and a negative sample; thirdly, simplifying a positive sample network module by utilizing a negative sample network module according to the experiment background; finally, clustering the characteristics according to the simplified positive sample network module, and establishing a lasso cluster and a promotion model of the lasso cluster according to the clustering. According to the method disclosed by the invention, the characteristic clustering of the lasso cluster is successfully and organically combined with module selection of network analysis, the operation is easy, the clustering method can be applied to screening of related genes in liver regenerative cell proliferation, and the method has an important application value in simulating a cell proliferation process of complicated diseases such as liver cirrhosis and cancer and screening new drugs.

The invention discloses a serum-free medium for stem cells. The serum-free medium comprises a basic medium, an additive and a cytokine combination, wherein in terms of the volume of the basic medium as reference, the additive comprises transferrin in a volume ratio of 5%-10%, insulin with concentration of 5-15 mg/L, 2-4 mM of L-glutamine, growth factors with concentration of 5-15 ng/mL, BMP-5 antibody with concentration of 0.05-0.25 ng/mL, 2-4 mM of a lipid complex and trace elements with concentration of 1-5 mg/L. The serum-free animal-derived components are adopted, so that interference of many uncertain substances (such as different antigens, antibodies, hormone and cytokines) contained in serum on in-vitro expansion survival rate and the cell proliferation process of hematopoietic stemcells is eliminated, the proliferation efficiency is increased, the quantity of high-activity hematopoietic stem cells is increased, use types and adding content of the cytokines in the in-vitro expansion process of the hematopoietic stem cells are adjusted, then the activity of the hematopoietic stem cells in in-vitro expansion is improved, and death rate of the cells can be reduced.

Compounds of formula (I):

as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The present invention relates to a method for detecting the immunosuppressive function of regulatory T cells, wherein the steps of the method include: purifying CD4+T cells and washing with PBS phosphate buffer; solution; add an equal volume of CFSE hydroxyfluorescein diacetate succinimide lipid, preheat PBS phosphate buffer 5 μM, the final concentration of CFSE hydroxyfluorescein diacetate succinimide lipid is 2.5 μM; incubate at room temperature 2 minutes; add an equal volume of fetal calf serum, incubate at room temperature for 1 minute; wash the complete medium 3 times, recount, add to a 96-well plate for 5 days; beneficial effects of the present invention: safe, and the labeled fluorescence can be maintained for several days Weekly; can track the process of cell division and proliferation in vivo; high correlation; specific tracking operation is simple and reliable; stable, objective results, cost-effective, and high efficiency.

The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

Provided are compounds of formula (I) as defined herein, and synthetic intermediates thereof, which are capable of modulating the KIF18A protein, thereby affecting the cell cycle and cell proliferation processes to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions comprising the compounds and methods for treating conditions associated with KIF18A activity.

The present invention relates to chemical compounds having a general formula (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

The present application describes polysaccharide compositions that can be used as modulators of cell proliferation processes and their use in tissue repair with fibrotic process inhibition. These modulation properties can be usefully used in tissue repair for the prevention of fibrotic processes and/or tissue adhesions in traumatic, post-surgical and chronic fibrotic processes associated to autoimmune diseases.

Since the death rate of melanoma is high, by developing a novel molecular therapeutic target for inhibiting cell proliferation of the melanoma, a laboratory basis for clinical treatment of the melanoma can be provided. MicroRNA (micro-RNA, for short, MiRNA) is non-coding micromolecular RNA of which the length is about 22 nucleotides, plays an important role in the cell proliferation process, has the advantages of being high in tissue specificity, not easy to degrade, easy to detect and the like, and is an ideal target of molecular targeted therapy. Therefore, the invention provides a construction method of a human miR-106b-5p (hsa-miR-106b-5p) interference fragment and application of the human miR-106b-5p interference fragment in the cell proliferation of the melanoma, which can provide anew experimental evidence for basic research and clinical treatment of the melanoma. The full name of miR-106b-5p is human micro ribonucleic acid-106b-5`end (hsa-miR-106b-5p), and the former name of the miR-106b-5p is hsa-miR-106b.